

Commercial/Healthcare Exchange PA Criteria

Effective: August 1, 2016

Prior Authorization: Doxepin Topical Creams

Products Affected: Prudoxin (doxepin hydrochloride) cream, Zonalon (doxepin hydrochloride) cream

Medication Description: Although doxepin HCl does have H1 and H2 histamine receptor blocking actions, the exact mechanism by which doxepin exerts its antipruritic effect is unknown. PRUDOXIN® Cream can produce drowsiness which may reduce awareness, including awareness of pruritic symptoms. In 19 pruritic eczema patients treated with PRUDOXIN® Cream, plasma doxepin concentrations ranged from nondetectable to 47 ng/mL from percutaneous absorption. Plasma levels from topical application of PRUDOXIN® Cream can result in CNS and other systemic side effects.

Covered Uses: Short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus.

Exclusion Criteria:

1. Patients with untreated narrow angle glaucoma
2. Patient with a tendency to urinary retention

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 10 days

Other Criteria:

- A. Patient has a diagnosis of moderate pruritis associated with atopic dermatitis OR lichen simplex chronicus; AND
- B. Patient has tried and failed previous treatment with at least TWO (2) topical steroid creams.

References:

1. doxepin HCl 5% topical cream, doxepin HCl 5% topical cream. Renaissance Pharma, Inc. (per DailyMed), Newtown, PA, 2015.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	8/2016
2	Update	Moved to updated template	All	2/2020